Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.

Annemans L, Brignone M, Druais S, De Pauw A, Gauthier A, Demyttenaere K.

Pharmacoeconomics. 2014 May;32(5):479-93. doi: 10.1007/s40273-014-0138-x.

2.

Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.

Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP.

CNS Drugs. 2015 Aug;29(8):695-712. doi: 10.1007/s40263-015-0267-6. Review.

PMID:
26293743
3.
4.

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.

Maniadakis N, Kourlaba G, Mougiakos T, Chatzimanolis I, Jonsson L.

BMC Health Serv Res. 2013 May 10;13:173. doi: 10.1186/1472-6963-13-173.

5.

Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model.

Ramsberg J, Asseburg C, Henriksson M.

PLoS One. 2012;7(8):e42003. doi: 10.1371/journal.pone.0042003. Epub 2012 Aug 2.

6.

C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.

Mencacci C, Aguglia E, Biggio G, Cappellari L, Di Sciascio G, Fagiolini A, Maina G, Tortorella A, Katz P, Ripellino C.

Adv Ther. 2013 Jul;30(7):697-712. doi: 10.1007/s12325-013-0046-z. Epub 2013 Aug 9.

PMID:
23929174
7.

Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.

Wade AG, Fernández JL, François C, Hansen K, Danchenko N, Despiegel N.

Pharmacoeconomics. 2008;26(11):969-81.

PMID:
18850765
9.

A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.

Armstrong EP, Malone DC, Erder MH.

Curr Med Res Opin. 2008 Apr;24(4):1115-21. doi: 10.1185/030079908X273309 . Epub 2008 Mar 7.

PMID:
18331669
10.
11.

Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.

Nordström G, Danchenko N, Despiegel N, Marteau F.

Value Health. 2012 Mar-Apr;15(2):231-9. doi: 10.1016/j.jval.2011.09.011. Epub 2012 Jan 27.

12.

Escitalopram: a pharmacoeconomic review of its use in depression.

Croom KF, Plosker GL.

Pharmacoeconomics. 2003;21(16):1185-209. Review.

PMID:
14594439
13.

A budget-impact and cost-effectiveness model for second-line treatment of major depression.

Malone DC.

J Manag Care Pharm. 2007 Jul;13(6 Suppl A):S8-18.

PMID:
17874482
14.

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy.

Mencacci C, Di Sciascio G, Katz P, Ripellino C.

Clinicoecon Outcomes Res. 2013;5:87-99. doi: 10.2147/CEOR.S39492. Epub 2013 Feb 7.

15.
16.

Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.

Choi SE, Brignone M, Cho SJ, Jeon HJ, Jung R, Campbell R, Francois C, Milea D.

Expert Rev Pharmacoecon Outcomes Res. 2016 Oct;16(5):629-638. Epub 2016 Jan 13.

PMID:
26641142
18.

Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria.

Hemels ME, Kasper S, Walter E, Einarson TR.

Curr Med Res Opin. 2004 Jun;20(6):869-78.

PMID:
15200745
19.
20.

Spotlight on the pharmacoeconomics of escitalopram in depression.

Croom KF, Plosker GL.

CNS Drugs. 2004;18(7):469-73. Review.

PMID:
15139801

Supplemental Content

Support Center